Prelude Therapeutics Incorporated

PRLD

$4.70

+$0.30 (6.82%)

Pre-Market

Disclosures of major OrbiMed, director, and institutional buys in recent $90M offering drive PRLD premarket surge.

Loading chart...

IndexN/A

Market Cap0.26B

Enterprise Value0.14B

Income$-0.03B

Sales$0.00B

EmployeesN/A

P/E-3.64

P/S18.38

P/B3.25

P/C-3.96

EV/EBITDA-1.40

EV/SalesN/A

EPS (ttm)-1.29

EarningsN/A

Gross Margin85.91%

Oper. Margin-861.33%

Profit Margin-819.59%

Volume0.87M

Shs Outstand0.08B

Change6.82%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Apr 2006:30AMPrelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering(globenewswire.com)06:00AMPrelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026(globenewswire.com)

Apr 1507:30AMPrelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer(globenewswire.com)

Apr 701:40AM

Insider Trading

View All

Insider

Type

Price

Value

Date

Huang Jane

Option

9.4K

—

Oct 4, 25

Huang Jane

3.4K

$1.47

$5K

Oct 4, 25

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

CEO: Krishna VaddiEmployees: 131www.preludetx.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Revenue	$7.00M	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$149.00K
Gross Profit	$7.00M	N/A	N/A	N/A	N/A	N/A	$-149.00K
Gross Margin	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$146.71M	$132.28M	$123.54M	$113.73M	$58.76M	$28.11M	$14.83M
Operating Income	$-139.71M	$-132.28M	$-123.54M	$-113.73M	$-58.76M	$-28.11M	$-14.97M
Operating Margin	-1995.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income	$-127.17M	$-121.83M	$-115.44M	$-111.69M	$-56.93M	$-27.57M	$-14.68M
Net Margin	-1816.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-1.68	$-2.02	$-2.27	$-2.33	$-1.30	$-0.85	$-9.31
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Prelude Therapeutics Incorporated

Insider Trading

Discover more